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Abstract
CD69 is rapidly upregulated on T cells upon activation. In this work we show that this is also the case for CD69 expression
on dendritic cells (DC). Thus, the expression kinetics of CD69 on both cell types is reminiscent of the one of costimulatory
molecules. Using mouse models of transgenic T cells, we aimed at evaluating the effect of monoclonal antibody (MAb)-
based targeting and gene deficiency of CD69 expressed by either DC or T cells on the extent of antigen (Ag)-specific T cell
priming, which could be the result of a putative role in costimulation as well as on DC maturation and Ag-processing and
presentation. CD69 targeting or deficiency of DC did not affect their expression of costimulatory molecules nor their
capacity to induce Ag-specific T cell proliferation in in vitro assays. Also, CD69 targeting or deficiency of transgenic T cells
did not affect the minimal proliferative dose for different peptide agonists in vitro. In in vivo models of transgenic T cell
transfer and local Ag injection, CD69 deficiency of transferred T cells did not affect the extent of the proliferative response in
Ag-draining lymph nodes (LN). In agreement with these results, CD69 MAb targeting or gene deficiency of Vaccinia-virus
(VACV) infected mice did not affect the endogenous formation of virus-specific CD8+ T cell populations at the peak of the
primary immune response. Altogether our results argue against a possible role in costimulation or an effect on Ag
processing and presentation for CD69.
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Introduction
CD69 is a type II C-type lectin of unknown ligand specificity
encoded in the NK-complex. It is known as a very early activation
marker, since it is promptly upregulated on all leukocytes upon
activation [1–2]. Importantly, it is upregulated on T cells by
IFNa/b [3], and upon Ag encounter [4–5], during the first
kinetics phase of brief contacts between T cells and antigen
presenting cells, either in the presence or absence of adjuvant [6].
CD69 expression has been reported in infections [7–10],
autoimmune diseases [11–16], and tumor infiltrates [17–18].
Some C-type lectins are upregulated on T cells upon activation
and have costimulatory or coinhibitory effects, influencing the
extent of TCR-mediated T cell activation [19–20]. Apart from
that, most C-type lectin receptors are expressed by DC [21], and
some of them have been shown to induce signaling or to influence
Toll-like receptors (TLR)-induced signaling, modulating the
maturation status of the DC [22]. This can affect their Ag
processing and presentation activity as well as surface expression of
co-stimulatory molecules and cytokine production, all of which
can influence the capacity of the DC for priming Ag-specific T
cells.
Traditionally, a costimulatory role was attributed to CD69,
since anti-CD69 monoclonal antibody (MAb) treatment of pre-
activated human leukocytes led to further activation. In the case of
T cells, the addition of anti-CD69 MAbs enhanced anti-CD3 and
PMA-induced proliferation [23–25] through increased interleukin
(IL)-2 and IL-2 receptor expression [26] [4]. However a later study
using CD692/2 mice argued against such a role, since Ag-specific
T cell proliferation was unaffected in vivo [27]. Even more in
contrast, our group proposed a negative regulatory role for CD69,
since tumor-bearing CD692/2 mice showed increased anti-tumor
immunity to NK sensible tumors [28]. That was consistent with
later in vivo results showing that CD692/2 mice had increased
incidence and severity of different T cell-dependent autoimmune
and inflammatory diseases such as Collagen II Induced Arthritis
[29], allergic asthma, skin contact hypersensitivity [30] and
autoimmune myocarditis [31]. CD692/2 mice also showed
increased susceptibility to Listeria monocytogenes (Lm) infection,
associated with enhanced type I and II interferon (IFN) responses
[10]. Interestingly, in the tumor, arthritis and contact hypersen-
sitivity models, the in vivo treatment with the anti-CD69 2.2 MAb
also led to increased anti-tumor [32], autoimmune [33] and
inflammatory responses [30]. However, this antibody has agonist
activity, since it induces a variety of downstream functional
outcomes in purified cell types, like IFNc secretion in NK cells
[32], IL-2 secretion in plasmacytoid DC [34], CD25 upregulation
in IL-2-treated T cells [34] and TGFb secretion when crosslinked
on anti-CD3-activated T cells [28]. In vivo, anti-CD69 2.2 MAb
treatment, but not CD69 gene deficiency, induced bystander
proliferation of memory-phenotype T cells [34].
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e48593
In this study, we revisit the question of a role for CD69 on T cell
costimulation and priming, which could contribute to the observed
effects of CD69 on the different T cell-dependent immune
responses. To this effect we use antibody-based targeting and
gene knock-out approaches in in vitro and in vivo transgenic T cell
mouse models as well as viral infection models. We expand the
study upon a possible effect of CD69 on the extent of T cell
priming, not only from its expression on T cells, but also from its
expression on the other cell type participating in T cell priming,
the dendritic cells. Our results point to that CD69 does not affect
the extent of T cell priming, suggesting that it does not function as




Balb/c, DO10.11 RAG22/2 Balb/c, C57BL/6 and OT-I
C57BL/6 mice, all both CD69+/+ and CD692/2, and OT-I
RAG12/2 C57BL/6, OT-II C57BL/6 and H-2 class I knockout
HLA-A*0201-transgenic [35] mice were bred and housed under
specific pathogen free conditions in the animal facilities of the Parc
Cientific de Barcelona, Barcelona, Instituto de Salud Carlos III, Madrid,
and the Walter and Eliza Hall Institute, Melbourne. CD692/2
mice had been backcrossed on the C57BL/6 and the Balb/c
backgrounds at least nine times [27]. All procedures involving
animals and their care were approved by the University of
Barcelona and ISCIII Ethics Committees and were conducted
according to institutional guidelines in compliance with local
(Generalitat de Catalunya decree 214/1997, DOGC 2450) and
international (Guide for the Care and Use of Laboratory Animals,
NIH 85–23, 1985) laws and policies. Unless otherwise stated,
C57BL/6 mice were used.
Antibodies and immunological reagents
The anti-CD69 2.2 mAb (IgG1 isotype) was generated in our
laboratory [32] by the fusion of NS-1 myeloma cells with spleen
cells from a CD692/2 mouse previously immunized three times
with mouse 300–19 pre-B cells. The Ab was purified from
concentrated hybridoma supernatants using a protein G column
(GE Healhtcare, Piscataway, NJ, USA), dialyzed extensively
against PBS, further purified by high-performance liquid chroma-
Figure 1. CD69 is upregulated on endogenous DC upon activation. A.–C. DC were purified from spleens of C57BL/6 mice and cultured with
CpG in various conditions. 10 cg/ml of anti-CD69 2.2 were added to control samples in order to block CD69 staining and provide a background
staining control. 10 mg/ml of Isotype control Ab were added to test samples. All samples were stained for the different DC subsets markers and for
CD69, and analyzed by flow cytometry. A. Overlay of CD69 expression between CD69 blocked control samples cultured with 0.03 mM CpG for 18h
(grey filled), and unblocked samples, uncultured (dashed line) or cultured with 0.03 mM CpG for 18h (solid line), gated on pDC (CD11cint, CD45RA+),
and cDC (CD11chi, CD45RA2). B. DC were cultured with 0.03 mM CpG during various time-spans and CD69 was assessed in pDC (CD11cint, CD45RA+)
and cDC (CD11chi, CD45RA2). C. pDC (CD11cint, CD45RA+), CD8+ cDC (CD11chi, CD45RA2, CD8+) and CD82 cDC (CD11chi , CD45RA2, CD82) were
analyzed for CD69 expression after 12h culture with different doses of CpG or without having been cultured. In B and C, CD69 levels are expressed as
the difference of CD69 MFI between the unblocked and blocked samples. Results representative of two similar experiments are shown.
doi:10.1371/journal.pone.0048593.g001
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Figure 2. CD69 is upregulated on BMDC upon activation. CD69+/+ or CD692/2 GM-CSF BMDC were treated with LPS at different conditions of
time and dose. Subsequently they were stained for CD11c and CD69, and analyzed by flow cytometry. A. Overlay of CD69 histograms of CD69+/+
untreated cells (dashed line), and CD69–/2 (grey filled) and CD69+/+ (solid line) cells cultured for 12h with 1 mg/ml of LPS (right). B. Time course of
CD69 upregulation in response to 1 mg/ml of LPS. CD69 expression is the difference in MFI between CD69+/+ and CD692/2 BMDC. C. CD69+/+ BMDC
were cultured for 24h with growing doses of LPS and with anti-CD69 2.2 (to provide a background staining control) or Isotype control. CD69 surface
expression is expressed as the difference in MFI between unblocked and blocked samples. Results are representative of two experiments with similar
CD69 Role on T Cell Priming
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e48593
tography (HPLC) using a Superdex 200 column (GE Healhcare,)
and stored at 280uC. The IgG1 isotype control antibody was
produced and purified likewise. The resulting antibody prepara-
tions were tested on CD692/2 bone marrow-derived DC (BMDC)
cultures at 10 mg/ml, and were unable to upregulate CD80 or
CD86 expression levels on these cells. Phosphorothioated CpG
oligodeoxynucleotide 1668 was from Geneworks (Hindmarsh,
Australia). Ovalbumin (OVA) and E. coli Lipopolysaccharide (LPS)
were from Sigma (St. Louis, MO, USA). The SIINFEKL was
synthesized by the Proteomics facility of the Instituto de Salud Carlos
III using a peptide synthesizer (model 433A; Applied Biosystems,
Foster City, CA, USA) and purified by reverse-phase HPLC. The
SIIGFEKL and the Catnb1 (b-catenin 329–336, RTYTYEKL)
were purchased from Peptide2.0 Inc. (Chantilly, VA, USA). All
cell line cultures and in vitro cultures were performed in complete
medium (RPMI medium 1640 supplemented with 10% FCS,
50 mM 2-mercaptoethanol, 2 mM L-glutamine, 100 units/mL
penicillin, and 100 mg/mL streptomycin) at 37uC.
Flow cytometry
LN and spleen cells were treated with anti-CD16/32 (Fc-block
2.4G2, BD Biosciences, Franklin Lakes, NJ), and 7-Aminoactino-
results. D. and E. CD69+/+ or CD692/2 Flt3l-derived BMDC were treated with various CpG doses for 24h and stained for the different DC subset
markers and CD69. D. Overlay of the CD69 histograms of 50nM CpG-treated CD692/2 (grey filled), and untreated (dashed line) or 50nM CpG-treated
(black line) CD69+/+ pDC (CD11c+, CD45RA+, left) and cDC (CD11c+, CD45RA2, right). E. CD69+/+ and CD692/2 BMDC were cultured with growing
doses of CpG for 24h. CD69 surface levels are expressed as the difference in MFI between CD69+/+ and CD692/2 BMDC. The results shown are of one
out of two similar experiments.
doi:10.1371/journal.pone.0048593.g002
Figure 3. CD69 deficient DC do not have altered priming capacity. A. CD69+/+ or CD692/2 Flt3l-derived BMDC were cultured with 0.5 mM
CpG for 24 h. Overlays of CD69+/+ (solid line) and CD692/2 (dashed line) Flt3l-derived BMDC showing CD86 and CD40 expression on pDC (CD11c+,
CD45RA+, left) and cDC (CD11c+, CD45RA2, right). B. and C. CD69+/+ or CD692/2 Flt3l-derived BMDC were pulsed with OVA at the indicated doses for
45 minutes, washed, and further cultured with OT-II (B.) or OT-I (C.) T cells for 3 or 2 days, respectively, in the presence of 0.5 mM CpG in duplicate.
Percentage of proliferated Va2+ CD4+ or Va2+ CD8+ cells is depicted. Bars represent Standard Deviation (SD) of duplicate cultures. Experiments
representative of two with similar results.
doi:10.1371/journal.pone.0048593.g003
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mycin D (7AAD, BD Pharmingen) or Propidium Iodide (Molec-
ular Probes, Eugene, OR, USA) were added in order to exclude
dead cells. The following antibodies against mouse surface
antigens were used: anti-CD4 (GK1.5), -CD8 (YTS 169.4), -
CD11c (N418), -CD40 (FGK45.5), -B220/CD45RA (14.8), -
CD69 (H1.2F3), -CD86 (PO3.1), and -Bst2 (120G8), all in-house
produced; -CD4 (GK1.5), -CD8 (53–6.7), -CD25 (PC61.5), -Va2
TCR (B20.1), and -DO10.11 TCR (KJ1), from eBioscience (San
Diego, CA, USA). Cells were analyzed on FACScan, FACScali-
bur, FACScanto or LSRII flow cytometers (Becton Dickinson,
Franklin Lakes, NJ USA), using CELLQuest or BD FacsDiva
software (Becton Dickinson) and data was analyzed with FlowJo
(Tree Star Inc., Ashland, OR, USA). In the experiments where the
Mean Fluorescence Intensity (MFI) is represented, this parameter
corresponds to the Geometric Mean.
BMDC generation
Bone marrows were lysed and cultured in complete medium.
For GM-CSF-derived BMDC, cells were cultured at 0.56106/ml
in 24 well plates in the presence of 20 ng/mL Granulocyte and
Macrophage Colony Stimulating factor (GM-CSF) (Immunotools,
Friesoythe, Germany) for 6 days, changing half of the media for
fresh media every two days. For Fms-related tyrosine kinase 3
ligand (Flt3l)-derived BMDC, cells were cultured at 1.56106/ml in
24well plates supplemented with in-house produced Flt3l for 9
days.
DC Isolation
Splenic DC were isolated as described [36]. Briefly, C57BL/6
spleens were digested with DNase I (0.1%, Roche Molecular
Biochemicals, Mannheim, Germany) and Collagenase (type II,
Worthington Biochemical, Lakewood, NJ, USA), and centrifuged
over Nycodenz medium (density 1.082 g/cm3, 17006 g for 10
Figure 4. CD69 targeting on DC does not alter their costimulation and priming capacity. A. Flt3l BMDC were cultured with 50 nM CpG
and anti-CD69 2.2 (solid line) or IgG1 control (dashed line) for 24 h. CD86 and CD40 expression levels were determined on pDC (CD11c+, CD45RA+,
left) and cDC (CD11c+, CD45RA2, right). Result representative of two experiments. B. Purified DC were cultured with OT-II CD4+ T cells, in the
presence of the indicated OVA doses, 0.03 mM CpG and 10 mg/ml anti-CD69 2.2 or IgG1 isotype control, in duplicate, for 3 days. C. Sorted pDC were
cultured with the indicated OVA doses and 10 mg/ml anti-CD69 2.2 or IgG1 isotype control for 1 h. After wash, they were co-cultured with CD4+ OT-II
T cells for 3 days. D. Sorted cDC were pulsed with the indicated OVA doses for 45 minutes and treated with 0.025 mM CpG and anti-CD69 2.2 or IgG1
control for 18 h. Then, they were cultured with OT-I CD8+ T cells for 2 days. In all cases, the number of divided cells within Va2+ CD8+ or Va2+ CD4+
live cells is represented. Bars represent SD of duplicate cultures.
doi:10.1371/journal.pone.0048593.g004
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min). The light-density fraction was treated with anti-CD3 (KT3-
1.1), anti-Thy1-1 (T24/31.7), anti-Ly6G (IA8), anti-CD19 (ID3)
and anti-erythrocyte (TER119), all home-produced, followed by
immunomagnetic depletion with sheep anti-ratIgG coated Dyna-
beads (Dynal Biotech, Oslo, Norway). Where indicated, DC were
stained with home produced anti-CD11c, -CD45RA and -Bst2
and further purified into conventional DC (cDC, CD11chi
CD45RA2 Bst22) or plasmacytoid DC (pDC, CD11cint
CD45RA+ Bst2+) with a FACS Aria sorter (Becton Dickinson).
In vitro cultures
For T-DC co-cultures, OT-I and OT-II LN T cells were
negatively selected using MAbs against CD11b (M1/70), F4/80,
Ter-119, Gr-1 (RB6), MHC class II (M5/114), and CD4 (GK 1.5)
or CD8 (YTS 169.4), respectively, followed by incubation with
anti-rat IgG-coupled magnetic beads (Dynal Biotech). T cell
preparations were 90–95% pure. T cells were stained with 5 mM
carboxyfluorescein succinimidyl ester (CFSE). DC were plated at
56103 per well in U-bottom 96 well plates and cultured in
complete media with the indicated conditions, in duplicate. Where
indicated anti-CD69 2.2 or IgG1 control were added at 10 mg/ml.
DC were co-cultured with 56104 OT-I CD8+ or OT-II CD4+ per
well for 2 or 3 days respectively. After that, cells were stained with
anti-Va2, PI and anti-CD8 or anti-CD4 MAbs. For cultures of
OT-I RAG12/2 cells with peptide doses, whole LN and spleen
cells were labeled with 2 mM CFSE and plated at 106 cells per well
in 96 well flat-bottom plates and were cultured with the indicated
peptide doses, 10 mg/ml of anti-CD69 2.2 or IgG1 and with or
without 1 mg/ml LPS for 3 days. For cultures of CD69+/+ or
CD692/2 OT-I cells with peptide doses, CD8+ T cells were
negatively purified using CD8+ T cell isolation Kit and MACs
columns (Miltenyi Biotec, Auburn, CA, USA), stained with 2 mM
CFSE and cultured at 0.56106 cells per well together with
0.56105 CD69+/+ antigen presenting cells (the positive fraction) in
96 well flat-bottom plates with the indicated peptide doses for 3
days. Cells were then stained for CD8 and CD25 and analyzed by
flow cytometry. 2.56104 Callibrite beads (Becton Dickinson) were
added to each sample, and samples were acquired until 5x103
beads had been collected.
In vivo cell transfers
OT-I CD8+ T cells or DO10.11 CD4+ T cells were purified
from CD69+/+ or CD692/2 OT-I or DO10.11 mice, respectively,
with CD8+ or CD4+ T cell isolation Kit and MACs columns
(Miltenyi Biotec). After that, they were stained with 5 mM CFSE
and injected intravenously into C57BL/6 or Balb/c recipients,
Figure 5. CD69 deficiency on T cells does not affect Ag-specific T cell proliferation in Ag-draining LN. A. Purified CD69+/+ or CD692/2
OT-I CD8+ T cells were CFSE stained and transferred into recipients receiving the indicated doses of OVA and 5 mg of LPS subcutaneously in a
posterior footpad. The percentage of proliferated OT-I CD8+ T cells was analyzed 42h later in the popliteal LN. Pool of two experiments, with 1 (dose
0) to 4 (doses 0.1–10 mg) mice per point. Bars represent SD. B. As in A, but mice received 10 mg of OVA with or without 5 mg of LPS in the footpad. C.
Purified CD69+/+ or CD692/2 RAG22/2 DO10.11 CD4+ T cells were transferred into Balb/c mice receiving 1 mg of OVA subcutaneously in the footpad.
3 days later the popliteal LN were analyzed for the percentage of proliferated cells within DO10.11 CD4+ T cells.
doi:10.1371/journal.pone.0048593.g005
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respectively. Transferred recipients were anesthetized and received
a subcutaneous injection in a posterior hind-footpad of the
indicated OVA doses in a 10 ml volume using a Hamilton syringe
(Hamilton Bonaduz, Bonaduz, Switzerland). At the indicated
times, popliteal LN were collected, stained with anti-CD8+ or anti-
CD4+ MAbs, and transferred cells were analyzed for CFSE
dilution.
Vaccinia virus infection and ex vivo intracytoplasmic
staining (ICS)
Infections and ICS were performed as described [37]. Briefly,
mice were infected with VACV-WR [38] or VACV-OVA257–264
(encoding the miniprotein MSIINFEKL) [39] with an intraperi-
toneal injection of 107 plate forming units. After 7 days, spleens
were harvested. For VACV-WR-infected mice, 106 spleen cells
were reestimulated with either RMA or RMA-S HLA-A*0201
cells infected with VACV-WR (at a multiplicity of infection of 10
plate forming units per cell for 2 h at 37uC, and washed), in the
presence of brefeldin A (5 mg/ml). For VACV- OVA257–264-
infected mice, 36106 spleen cells were reestimulated for 4h with
SIINFEKL in the presence of brefeldin A (5 mg/ml). Cells were
then surface-stained with anti-CD8 MAb (ProImmune, Oxford,
United Kingdom), fixed with 4% paraformaldehide, washed, and
incubated with anti-IFNc MAb (BD PharMingen, San Diego, CA)
in the presence of 0.1% saponin for 20 min at 4uC. Events were
acquired and analyzed by flow cytometry as described.
Results
CD69 is upregulated on DC upon activation
CD69 upregulation on T cells upon specific Ag encounter has
been well documented. Instead, CD69 expression by the other
Figure 6. CD69 targeting does not alter CD8+ T cell priming threshold at different peptide agonistic affinities. Whole LN and spleen
OT-I RAG12/2 cells were stained with 2 mM CFSE and cultured at 106 cells per well with the indicated doses of SIINFEKL (A), SIIGFEKL (B), Catnb1 (C)
and Catnb1 plus 1 mg/ml of LPS (D), and 10 mg/ml of anti-CD69 2.2 mAb (dashed line) or isotype control (solid line). Graphs showing the number of
proliferated (left column) and of CD25+ (right column) CD8+ T cells per well. Results representative of two experiments.
doi:10.1371/journal.pone.0048593.g006
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prototypic cell type implicated in T cell priming, the DC, has not
been extensively studied. We have recently described certain
constitutive CD69 expression by lymph node (LN) and spleen
plasmacytoid DC (pDC) and by LN conventional DC (cDC) at
steady state [34]. Here, we assess activation-induced CD69
upregulation on different DC subsets, activating them with Toll-
like Receptors (TLR) ligands. CD69 was upregulated on both
splenic pDC and cDC upon CpG olidodeoxynucleotide stimula-
tion (Fig. 1A) in a dose-dependent manner (Fig. 1C), and it was
prominent as soon as 3 hours after activation (Fig. 1B). CD69
upregulation was much higher in pDC than in the cDC subsets,
which has been observed previously [40], and within the cDC
subset, it was more prominent in CD8+ cDC than in CD82 cDC
(Fig. 1C). After 12 hours culture in the absence of CpG, there was
also a marked CD69 upregulation on splenic DC (Fig. 1C),
consistent with the activation that ex vivo purified DC undergo in
culture [41]. CD69 was not expressed by unstimulated Granulo-
cyte-Macrophage Colony Stimulating Factor (GM-CSF) and Fms-
related tyrosine kinase 3 ligand (Flt3l)-derived Bone Marrow DC
(BMDC), but it was upregulated on GM-CSF BMDC when we
treated them with Lipopolysaccharide (LPS) (Fig. 2A) and on Flt3l
BMDC when we treated them with CpG (Fig. 2D), in both cases in
a dose dependent manner (Fig. 2B, E). Therefore, CD69 is
upregulated on endogenous DC upon activation with TLR
ligands, and this induced expression can be reproduced in in
vitro-generated BMDC models.
CD69 deficiency or targeting on DC do not affect their
costimulation or Ag-presentation capacity
We next aimed at studying whether this CD69 expression by
DC can have a role in T cell priming by putatively influencing
costimulation or Ag presentation. To this end, we analyzed the
effect of DC CD69 deficiency on the extent of the proliferation
undergone by Ag-specific T cells, as well as on the expression of
costimulatory molecules by DC. CD69 deficiency did not affect
CD86 or CD40 expression on CpG-activated Flt3l-derived
BMDC (Fig. 3A), and did not alter Ag-specific T cell proliferation
in in vitro co-cultures of ovalbumin (OVA)-pulsed CD69+/+ or
CD692/2 Flt3l-derived BMDC with OVA-specific, transgenic
OT-I CD8+ or OT-II CD4+ T cells (in the presence of CpG to
induce CD69 expression) (Fig. 3B, C). We also analyzed whether
MAb-based engagement of CD69 expressed on DC could have an
effect on their Ag-presenting capacity. CD69 targeting with the
anti-CD69 2.2 MAb in in vitro co-cultures of purified DC and OT-
Figure 7. CD69 deficiency does not alter CD8+ T cell priming threshold at different peptide agonistic affinities. Spleen CD8+ T cells
were purified from CD69+/+ (solid line) or CD692/2 (dashed line) OT-I mice, stained with 2 mM CFSE and cultured at 0.56106 at 10:1 with APC in the
presence of the indicated doses of SIINFEKL (A), SIIGFEKL (B), and Catnb1 (C) peptides. Graphs showing the number of proliferated (left column) and
of CD25+ (right column) CD8+ T cells per well. The results are representative of two similar experiments with similar results.
doi:10.1371/journal.pone.0048593.g007
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II cells in the presence of CpG and various OVA doses did not
affect the OT-II proliferative response (Fig. 4B). In the co-culture
of anti-CD69 2.2-treated pDC with OT-II cells (Fig. 4C) the
proliferation was also unaltered. The treatment of cDC (contain-
ing the cross-presenting CD8+ DC subset) with anti-CD69 2.2 in
the presence of CpG did not alter their cross-priming of OT-I cells
(Fig. 4D). Consistently, treatment of CpG pre-activated Flt3l-
derived BMDC with anti-CD69 2.2 did not affect the surface
expression of CD86 and CD40 (Fig. 4A). Thus, CD69 expression
or CD69 targeting on DC does not affect their costimulation or Ag
presentation capacity to Ag-specific T cells.
CD69 deficiency on T cells does not affect Ag-specific T
cell proliferation in Ag-draining LN in vivo
CD69 has been well documented to be upregulated on T cell in
response to the encounter with specific Ag. We thus wanted to
assess whether CD69 could function as a costimulatory molecule
on T cells. To analyze the effect of T cell CD69 deficiency on Ag
priming in vivo, we transferred CD69+/+ or CD692/2 OT-I cells
into recipients receiving OVA subcutaneously into the footpad. In
this setting, CD69 deficiency on T cells did not affect T cell
proliferation in the popliteal LN of recipients injected with various
OVA doses plus LPS (Fig. 5A) or 10 mg of OVA with or without
LPS (Fig. 5B). A similar observation was made using the DO10.11
transfer model, in which CD69 deficiency did not affect
proliferation of transferred OVA-specific transgenic DO10.11
CD4+ T cells in popliteal LN of recipients receiving OVA
subcutaneously in the footpad (Fig. 5C). These results suggest that
CD69 deficiency on T cells does not affect the extent of their Ag-
specific priming in vivo.
CD69 MAb-targeting or gene deficiency on Ag-specific
CD8+ T cells do not alter the activation threshold at
varying peptide agonistic levels in vitro
We further investigated the effect of CD69 targeting and
deficiency on the extent of proliferation in in vitro cultures of
transgenic CD8+ T cells with different agonist peptides.
The anti-CD69 2.2 MAb has been shown to bind to TCR-
activated T cells [28]. However, the addition of this antibody to
whole LN and spleen OT-I RAG12/2 cultures with growing
SIINFEKL peptide doses did not affect the dose from which T cell
proliferation and CD25 upregulation started (Fig. 6A). This is
consistent with our recently published in vivo results, in which anti-
CD69 2.2 treatment does not alter proliferation of OT-I
transferred T cells in Ag-draining LN of OVA-bearing mice
[34]. Reasoning that SIINFEKL might be a too strong agonist and
Figure 8. CD69 does not affect the primary formation of Vaccinia virus-specific CD8+ T cell populations. A. CD69+/+ or CD692/2 mice
were infected with VACV-WR and 7 days later spleen cells were reestimulated with uninfected (background control) or VACV-WR-infected RMA cells.
B. CD69+/+ or CD692/2 mice were infected with VACV-OVA and 7 days later spleen cells were reestimulated with or without (background control)
SIINFEKL peptide. Pool of two experiments. C. H-2 class I knockout HLA-A*0201-transgenic mice were i.v. treated with 100 mg of anti-CD69 2.2 or left
untreated, and were subsequently infected with VACV-WR. After 7 days, spleen cells were reestimulated with uninfected (background control) or
VACV-WR-infected HLA-A*0201 transfectant RMA cells. In all cases, cells were stained for intracellular IFNc, and the percentage of IFNc+ CD8+ T cells
within total cells was assessed. The background control values were substracted from each reestimulated sample value.
doi:10.1371/journal.pone.0048593.g008
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that a role in costimulation would be better noticed using weaker
agonist peptides, we used the SIIGFEKL peptide variant and the
Catnb1 peptide (an endogenous peptide from the b-catenin
protein mediating positive thymic selection of the OT-I clone). In
both cases, anti-CD69 2.2 MAb addition neither affected the
activation threshold, the extent of the proliferative response, nor
CD25 expression (Fig. 6B, C). We have also recently shown that
anti-CD69 2.2 induces bystander T cell proliferation in vivo and in
vitro, dependent on IL-2 production by pDC and CD25
upregulation by T cells. In vitro, for CD8+ T cells, this bystander
proliferation was observed when LPS was added to whole LN and
spleen cultures. It is unclear whether bystander proliferation
depends on the contact of the TCR with MHC molecules
presenting endogenous weak agonist peptides. In an attempt to
address this question, we added LPS to OT-I RAG12/2 cultures
with Catnb1 peptide. If the anti-CD69 2.2-induced bystander
proliferation was dependent on the recognition of endogenous
weak agonist peptides, the difference in proliferation between the
isotype control and the anti-CD69 2.2-treated samples would be
higher at higher Catnb1 peptide occupancy of the MHC-I, that is,
at higher Catnb1 peptide doses. However, this difference was
already maximal in the absence of peptide, was maintained
through a range of growing peptide doses, and disappeared at
peptide doses giving maximal proliferation (Fig. 6D). This suggests
that this bystander proliferation might be rather independent of
TCR recognition of endogenous weak agonist ligands. In
agreement with this hypothesis, anti-CD69 2.2 treatment induced
bystander proliferation of DO10.11 CD4+ T cells when these were
transferred into CIITA2/2 recipients, which have deficient MHC-
II expression, to the same extent as when they were transferred
into WT mice (our unpublished data). In Fig. 6D, as expected
from previous results, in the presence of LPS and in the absence of
peptide or at low peptide doses, the anti-CD69 2.2 induced CD25
upregulation on CD8+ T cells. Similarly to CD69 targeting, we did
not find a significant effect of CD69 deficiency on the CD8+ T cell
activation threshold, as measured by the peptide dose from which
T cell proliferation and CD25 upregulation start to be apparent
(even though the extent of proliferation and CD25 upregulation
were slightly lower for CD692/2 OT-I cells than for CD69+/+
OT-I cells). This was true for the three peptides tested (Fig. 7).
These results point to that CD69 does not function as a
costimulatory molecule on T cells.
Neither CD69 targeting nor CD69 deficiency affect the
formation of virus-specific CD8+ T cell populations in the
primary immune response to Vaccinia virus infection
To check for a possible role of CD69 expressed by either DC or
T cells on T cell priming in a physiological model of infection, in
which more factors and possible indirect effects can also play a
role, we used various experimental settings of the Vaccinia virus
(VACV) infection model. CD69 deficiency of VACV-WR (wild
type) (Fig. 8A) or VACV-OVA (Fig. 8B) -infected mice did not
alter the formation of the VACV- or SIINFEKL-specific CD8+ T
cell pools, respectively, as measured by the percentage of IFNc
producing spleen CD8+ T cells in response to VACV or
SIINFEKL reestimulation at the peak of the primary immune
responses. To test for the effect of anti-CD69 2.2 treatment on the
anti-Vaccinia virus CD8+ T cell response, we took advantage of
the availability of the H-2 class I knockout HLA-A*0201-
transgenic mouse model, whose surface MHC-I expression is only
the one of HLA-A2. In these mice, the MAb treatment did not
affect the percentage of CD8+ T cells responding to HLA-A2-
presented Vaccinia virus antigens either (Fig. 8C). These results
indicate that neither CD69 targeting nor CD69 deficiency affects
the primary expansion and formation of Ag-specific CD8+ T cell
pools, at least in the Vaccinia virus infection model.
Discussion
CD69 has been found to be rapidly upregulated on all the
leukocyte lineages studied, upon activation with the corresponding
stimuli. When testing whether this was also the case for DC, we
found that CD69 is upregulated on this cell type as soon as 3 hours
after addition of TLR ligands. Thus, the expression pattern of
CD69 on both T cells and DC is reminiscent of the one of
costimulatory molecules. Some C-type lectins are upregulated
upon activation on T cells, and have a costimulatory or
coinhibitory role on Ag-driven T cell activation, influencing,
among other parameters, the proliferative response. Also, C-type
lectins expressed on DC can initiate signaling or modulate TLR
signaling, affecting DC maturation and thus, possibly altering their
Ag presentation and costimulation abilities. In this work we have
examined a possible role for CD69 in the mentioned processes
through analyzing the effect of CD69 targeting and deficiency on
the extent of T cell priming.
In vitro, we did not observe any effect of CD69 deficiency or
targeting of DC using different DC types, OT-I or OT-II
responders and graded OVA doses. In addition, neither CD69
targeting nor its deficiency on T cells influenced the minimal
peptide dose needed for a proliferative response of OT-I T cells to
different peptides, not even to the weak agonist ones. In contrast to
CD69 deficiency, the deficiency of costimulatory molecules such as
CD28 has been observed to lead to the lack of T cell priming to
weak agonist peptides, even at high doses [42]. Consistent with the
in vitro results, in in vivo adoptive transfers of transgenic OT-I CD8+
or DO10.11 CD4+ T cells into recipient mice receiving OVA
subcutaneously in the footpad, CD69 deficiency did not affect the
extent of the Ag-driven T cell proliferation in the Ag draining LNs.
By parallel experimental approaches, we have previously reported
that CD69 deficiency [10] or anti-CD69 2.2 treatment [34] of the
recipient mice do not affect T cell cross-priming. All these data
point to that CD69 does not quantitatively affect the priming of
Ag-specific T cells.
In a recent work we have shown that, in the absence of specific
Ag, CD69 targeting with the anti-CD69 2.2 MAb induces
bystander T cell proliferation dependent on IL-2 and on CD25
upregulation on T cells (in vitro, for CD8+ T cells, it needed the
addition of LPS). This might seem contradictory with the results
shown in the present work, and also with the results in that same
work showing that anti-CD69 2.2 in vivo treatment did not affect
Ag-specific T cell proliferation, since one might expect that the
increased IL-2 and CD25 expression would lead to increased Ag-
specific proliferation. However it is possible that in the presence of
specific Ag, the TCR signaling itself already induces the
production of such IL-2 and CD25 amounts that overrule the
ones induced by CD69 targeting. Alternatively, in the presence of
TCR ligation, CD69 could be uncoupled from the downstream
signaling events leading to the bystander proliferative effect. These
hypotheses are consistent with the data shown in Fig. 5D, in which
the addition of LPS allows anti-CD69 2.2-induced bystander T
cell proliferation in the absence of Ag. In this experiment, the
difference of proliferation versus the wells with isotype control is
already maximal in the absence of peptide, is maintained during a
range of growing specific peptide doses, suggesting that the
bystander proliferation is added on top of the Ag-specific
proliferation, and disappears at the dose that gives a maximal
response.
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Our results are in contrast with the initial in vitro data showing
that anti-CD3 or PMA-activated human T cells were further
induced to proliferate by CD69 targeting, but are in agreement
with a posterior observation indicating that Ag-specific T cell
proliferation was unaffected in CD692/2 mouse T cells in vivo
[27]. Of notice, not all the anti-CD69 MAbs tested in initial works
were reported to have this proliferation-enhancing effect on
human T cells [43–44]. Altogether, more physiological in vitro and
in vivo data argue against the initially proposed role for CD69 as a
costimulatory molecule.
When studying the influence of CD69 in a physiological setting
in which the priming occurs to endogenous naı̈ve T cell pools of
various frequencies and TCR affinities, such as the Vaccinia virus
infection, we observed that CD69 targeting or deficiency did not
alter the size of the VACV-specific T cell population at the peak of
the primary response. This is in support of our previous hypothesis
that, if we found a slightly smaller population of Lm-specific T cells
in Lm-infected CD692/2 mice [10], it was not due to an intrinsic
defect in Ag-specific T cell priming. Instead, it could be a collateral
effect of the Lm-induced, type I IFN-mediated massive lympho-
cyte apoptosis [45] affecting also primed Lm-specific T cells. Of
notice, the defect in the control of Lm infection in CD692/2 mice
was noticeable as soon as day 1 post-infection (and thus, induced
by differences in the innate immune response), was associated to
increased type I IFN levels and increased spleen cell death, and
was not observed in lymphocyte deficient mice. In contrast to Lm
infection, Vaccinia virus infection does not lead to massive
lymphocyte apoptosis, and this might be the reason for it not
inducing this innate immunity-based difference in the size of
specific T cell populations.
Altogether, the in vivo and in vitro data point to that targeting of
CD69 expressed or up-regulated on DC does not affect their Ag
processing, Ag presentation or costimulation capacity, and that
CD69 does not function as a costimulatory molecule on DC or on
T cells. These results do not rule out, though, that CD69 could
affect other important aspects influencing or being determined by
DC-T cell interaction, such as DC polarization or T cell
polarization and programming. In this regard, CD69 has recently
been reported to inhibit Th17 differentiation in Ag primed CD4+
T cells [46]. Taking this into account, it could be hypothesized
that the exacerbated forms of Ag-specific T cell-dependent
diseases reported in CD692/2 and anti-CD69 2.2-treated mice
are not due to differential priming of Ag-specific T cells but might
rather be owed to skewed polarization of primed T cells.
On the whole, this work contributes to resolving a previous
controversy and to shift the focus on CD69 towards its effect on T
cell polarization, as it is starting to be apparent, rather than on the
extent of T cell priming and T cell costimulation.
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